GLIMEFON-M2 is a fixed-dose combination of Glimepiride, a sulfonylurea that stimulates
pancreatic insulin secretion, and Metformin, a biguanide that reduces hepatic glucose
production and enhances peripheral insulin sensitivity. This combination is ideal for patients
requiring stronger glycemic control.

Key Benefits:
● Dual-action therapy targets insulin deficiency and resistance
● Effective in lowering both fasting and postprandial blood glucose
● Helps achieve target HbA1c levels
● Delays progression of type 2 diabetes and prevents complications
● Convenient once or twice daily dosing
● Suitable for long-term glycemic control with good tolerability

Indications:
● Type 2 Diabetes Mellitus (in patients inadequately controlled on monotherapy)
● Recommended for patients requiring intensified antidiabetic treatment
● Reduces risk of microvascular and macrovascular complications